NEW YORK, July 30 – MDS Proteomics of Toronto unveiled Monday a new method designed to directly identify known and unknown proteins based on mass spectrometry data.
Using advanced algorithms developed by Matthias Mann, chief proteomics officer of MDS Proteomics, the PepSea technology is designed to identify any protein and to locate and identify the genes the encode the proteins.
"By allowing protein identification directly in raw human genome sequence, PepSea enables us to determine the identity and location of any human gene given an absolute minimum amount of protein," Mann said in a statement.
MDS has added PepSea to its bioinformatics platform.
The announcement follows another commercial breakthrough in proteomics. Last week, Oxford Glycosciences said it had successfully integrated the Isotope Coded Affinity Tag technology for measuring relative quantities of expressed proteins with the MALDI TOF/TOF, new mass spectrometry system.
OGS said that integrating the two new technologies with its established platform for 2D gel electrophoresis would enable the company to analyze proteins isolated from human samples at 10 to 1,000 times the rate they could before.
MDS said PepSea would ultimately allow the company to identify drug targets more quickly.
"Our integrated proteomics platform will lead the way to the discovery of many novel proteins and post-translational modifications, which are implicated in disease," said Frank Gleeson, CEO of MDS Proteomics.
"We expect this combination of technologies and expertise to broaden the scientific base from which, we and our pharmaceutical partners, will ultimately develop new therapeutic and diagnostic products," Gleeson said.
Using its IBM supercomputing cluster, MDS said it could search the entire human genome in under five seconds.
MDS, which did not disclose how PepSea works, was not immediately available for comment.